MiMedx Group Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +24.4% | +42.2% | -37.3% | +1.3% | +0.0% | +64.5% | -7.0% | -8.8% | +39.4% | +10.4% | +29.8% | |
| – | +12.4% | +31.4% | -61.5% | +51.9% | +0.0% | +116.9% | -7.5% | -9.6% | +22.4% | +16.8% | +44.6% | |
| – | -38.8% | +20.7% | -20.1% | +64.2% | +0.0% | +112.4% | -9.1% | -24.3% | +24.3% | +27.3% | +59.1% | |
| – | -39.8% | +9.2% | -20.1% | +64.2% | +0.0% | +112.4% | -9.1% | -24.3% | +24.3% | +27.3% | +59.1% | |
| – | +101.5% | +24.9% | -99.0% | -30.8% | +0.0% | +7,702.4% | +13.9% | +6.8% | +25.0% | +3.6% | +35.6% | |
| – | +45.3% | +138.8% | -46.9% | +68.9% | +0.0% | -35.2% | +9.9% | +15.8% | +59.5% | +13.3% | +6.4% | |
| – | +73.9% | +45.5% | +2.2% | +23.7% | -9.8% | -27.3% | +21.2% | -18.8% | – | – | – | |
| – | +0.0% | +400.1% | -1.1% | +0.0% | +0.0% | +0.0% | +0.0% | -2.7% | +0.0% | +0.0% | +0.0% | |
| – | -0.8% | +116.2% | -56.9% | -4.2% | +0.0% | -37.5% | -10.3% | +8.7% | -10.2% | +121.2% | +21.8% | |
| – | +40.1% | +115.8% | -21.2% | +54.2% | +0.0% | +51.1% | -13.8% | +1.6% | -0.6% | -26.5% | +21.6% | |
| – | +45.5% | +89.5% | -9.7% | +56.2% | +0.0% | -17.3% | -28.4% | +2.8% | +5.6% | -0.9% | +40.9% | |
| – | – | – | – | – | – | -68.6% | +6.1% | +15.4% | +7.5% | +49.0% | +22.2% | |
| – | +81.2% | +72.4% | -26.1% | +75.8% | +0.0% | -41.0% | -15.7% | +14.5% | +7.0% | -18.1% | +96.1% | |
| – | – | -93.5% | – | – | – | -23.0% | +0.9% | +1.0% | -1.0% | -62.9% | -7.6% | |
| – | +20.9% | +23.2% | -44.5% | -32.7% | +0.0% | +84.1% | +1.3% | -19.5% | +91.6% | +35.3% | +32.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.3% | -0.9% | +3.1% | -6.0% | -3.2% | +2.5% | +1.9% | +2.3% | +29.3% | +2.1% | +0.5% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.